SCHEDULE 13G: JPMorgan Chase & Co. Discloses 6.1% Stake in Cartesian Therapeutics, Inc.

JPMorgan Chase & Co. has filed a Schedule 13G, revealing a beneficial ownership of 6.1% in Cartesian Therapeutics, Inc.'s common stock as of March 31, 2025.

Summary

• JPMorgan Chase & Co. reported beneficial ownership of 1,675,636 shares of Common Stock in Cartesian Therapeutics, Inc.
• This ownership represents 6.1% of the total outstanding shares of Cartesian Therapeutics, Inc.'s common stock.
• The filing was made under Rule 13d-1(b), indicating that JPMorgan Chase & Co. is a parent holding company or control person.
• JPMorgan Chase & Co. holds sole voting power over 1,569,254 shares and sole dispositive power over 1,674,036 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Subsidiaries involved in the beneficial ownership include J.P. Morgan Securities LLC, JPMorgan Chase Bank, National Association, and J.P. Morgan Investment Management Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative performance indicators or forward-looking statements.

Future Outlook

This document is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance or operations.

Industry Context

This Schedule 13G filing indicates a significant institutional investment by JPMorgan Chase & Co. in Cartesian Therapeutics, Inc., a common practice for large financial institutions managing diverse portfolios. Such filings provide transparency into major ownership stakes, which can be viewed by the market as a vote of confidence or a strategic investment by a prominent financial entity.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.
• Investment Professionals: Offers insight into institutional investment strategies and portfolio holdings.

Key Dates

Keywords

JPMorgan Chase & Co., Cartesian Therapeutics Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing, Equity Stake, Financial Disclosure